ClinicalTrials.gg
RecruitingNCT06575140APS-PILOTUpdated Aug 30, 2024

Associative Peripheral Stimulation for Reduction of Motor Impairment During Acute Period of Stroke Recovery

An interventional study of Associative Peripheral Stimulation (APS) 1.0 and Peripheral Neuromuscular Stimulation in Stroke, Stroke, Acute and Stroke, Ischemic, sponsored by Ahmed A. Rahim. Recruiting at 3 sites in Mexico. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-08-30.

Sponsored by Ahmed A. Rahim · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Stroke with a site in Mexico — 11 open to participants now, 14 under way, 3 of them phase 3. Stroke · Mexico.

Planned enrollment
38th of 39
20 · median 5,081
Started
2021
with 1 other
No phase
7 of 52
4 open now
Primary completion
2024-12
later than 3 of 13 live
Registered
34th of 52
by date

Among the 52 studies in Stroke with a site in Mexico, this one is the 38th largest by planned enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 34th registered.

Stroke

8,281 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

11 of the 52 studies in Stroke with a site in Mexico are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Stroke with a site in Mexico, or all of them as a file.
02

Study summary

Associative Peripheral Stimulation (APS) is a non-invasive therapy intended for stroke rehabilitation involving transcutaneous electrical muscle stimulation paired with voluntary movement. This pilot study investigates whether APS applied during the acute phase of stroke recovery may reduce impairment and improve function in the affected upper extremity.

03

Conditions studied

  • Stroke
  • Stroke, Acute
  • Stroke, Ischemic
  • Stroke, Hemorrhagic
  • Hemiparesis
  • Hemiparesis;Poststroke/CVA
  • Weakness of Extremities as Sequela of Stroke
  • Stroke Sequelae
  • Upper Extremity Paresis

Keywords

  • Stroke Rehabilitation
  • Associative Peripheral Stimulation
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed ischemic or hemorrhagic stroke no earlier than 7 days prior to enrollment;
  2. Presentation of hemiparesis or paralysis of the upper extremity due to stroke;
  3. Ability to comprehend and follow study instructions;
  4. Ability to initiate finger extension (≥3°) at least three times per minute;
  5. Fugl-Meyer Assessment (Upper Extremity) score of \<47.

Exclusion criteria

Exclusion Criteria:

  1. , intolerance, or high sensitivity to the experimental protocol;
  2. History of upper-extremity disability prior to the index stroke;
  3. Neurological conditions (other than stroke) affecting motor function;
  4. Treatment of spasticity/increased tone in the affected upper extremity (e.g., with Botox injection);
  5. Lack of access to a safe and suitable place of discharge for experimental sessions and follow-up visits.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Group A

    Treatment

    Device: Associative Peripheral Stimulation (APS) 1.0

  • Active comparator
    Group B

    Control

    Device: Peripheral Neuromuscular Stimulation

Interventions

  • DeviceAssociative Peripheral Stimulation (APS) 1.0

    Associative peripheral stimulation paired with rehabilitative exercises.

  • DevicePeripheral Neuromuscular Stimulation

    Random peripheral stimulation paired with rehabilitative exercises.

06

What researchers measure

Primary outcomes

  1. Maximum Average of Range of Motion (ROM)

    Measure of distal extensor function (wrist and fingers). Unit of measurement: degrees (°). Higher scores indicate better outcomes.

    Time frame: 5 weeks

  2. Fugl-Meyer Assessment Upper-Extremity (FMA-UE)

    Measure of motor recovery in stroke patients with hemiparesis. Scoring range: 0 to 66. Higher scores indicate better outcomes.

    Time frame: 5 weeks

Secondary outcomes

  1. Maximum Average of Range of Motion (ROM)

    Measure of distal extensor function (wrist and fingers). Unit of measurement: degrees (°). Higher scores indicate better outcomes.

    Time frame: 3 months

  2. Fugl-Meyer Assessment Upper-Extremity (FMA-UE)

    Measure of motor recovery in stroke patients with hemiparesis. Scoring range: 0 to 66. Higher scores indicate better outcomes.

    Time frame: 3 months

  3. Action Research Arm Test (ARAT)

    Measure of four functional domains: grasp, grip, pinch, and gross arm movement. Scoring Range: 0 to 57. Higher scores indicate better outcomes.

    Time frame: 5 weeks

  4. Action Research Arm Test (ARAT)

    Measure of four functional domains: grasp, grip, pinch, and gross arm movement. Scoring Range: 0 to 57. Higher scores indicate better outcomes.

    Time frame: 3 months

07

Study locations

3 of 3 sites recruiting
  • General Hospital of Mexico
    Mexico City, Mexico
    Recruiting
    • Claudia Elisa Alfaro Tapia, MD · Contact
  • La Raza National Medical Center
    Mexico City, Mexico
    Recruiting
    • Jonathan Isaí Colín Luna, MD · Contact
  • National Institute of Neurology & Neurosurgery
    Mexico City, Mexico
    Recruiting
    • Daniel San Juan Orta, MD · Contact
08

References and documents

Individual participant data

Plan to share: No — Individual participant data shall not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2024, 36 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 36 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2019
First posted
Aug 28, 2024
StartActual
Dec 18, 2021
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Aug 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06575140
Lead sponsor
Ahmed A. Rahim
Responsible party
Ahmed A. Rahim (Sponsor-Investigator, APS Trial Group) — Sponsor-investigator
First posted
Aug 28, 2024
Start date
Dec 18, 2021
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Aug 30, 2024

Study contacts

Ahmed A Rahim, MTM
Contact
ahmed.rahim@alumni.ucsf.edu
+1 (916) 825-8792
Daniel San Juan Orta, MD
study director · National Institute of Neurology & Neurosurgery

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion